IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses

Vaccine. 2006 Jun 29;24(26):5461-72. doi: 10.1016/j.vaccine.2006.03.071. Epub 2006 Apr 7.

Abstract

IC31, the combination of a novel immunostimulatory oligodeoxynucleotide containing deoxy-Inosine/deoxy-Cytosine (ODN1a) and the antimicrobial peptide KLKL(5)KLK, represents a promising novel adjuvant signaling via the TLR9/MyD88-dependent pathway of the innate immune system. In mice, IC31 induces potent peptide-specific type 1 cellular immune responses, as well as mainly type 1 dominated protein-specific cellular and humoral immune responses. In addition, cytotoxic T lymphocytes were induced, able to kill efficiently target cells in vivo. Activation of murine dendritic cells by IC31 induced efficiently proliferation of naïve CD4(+) TCR transgenic T cells (DO.11.10) as well as their differentiation into IFN-gamma- and IL-4-producing T cells in vitro.

MeSH terms

  • Adaptor Proteins, Signal Transducing / metabolism
  • Adjuvants, Immunologic / pharmacology*
  • Animals
  • Cell Differentiation
  • Cell Proliferation
  • Dendritic Cells / drug effects
  • Dose-Response Relationship, Drug
  • Mice
  • Mice, Inbred C57BL
  • Myeloid Differentiation Factor 88
  • Ovalbumin / immunology
  • Signal Transduction / physiology*
  • T-Lymphocytes / drug effects
  • Toll-Like Receptor 9 / metabolism*

Substances

  • Adaptor Proteins, Signal Transducing
  • Adjuvants, Immunologic
  • Myd88 protein, mouse
  • Myeloid Differentiation Factor 88
  • Toll-Like Receptor 9
  • Ovalbumin